Aurogra is a prescription medication specifically formulated to address erectile dysfunction (ED) in adult men. It contains Sildenafil Citrate, a potent phosphodiesterase type 5 (PDE5) inhibitor that enhances blood flow to the penile tissues, facilitating the achievement and maintenance of an erection sufficient for satisfactory sexual activity. This medication is intended for use only when clinically indicated and under appropriate medical supervision, as it requires consideration of individual health status and potential contraindications. Proper diagnosis and ongoing management are essential to ensure both safety and therapeutic efficacy.

Features

• Active ingredient: Sildenafil Citrate 100mg
• Mechanism: Selective inhibition of phosphodiesterase type 5 (PDE5)
• Onset of action: Typically within 30–60 minutes post-administration
• Duration of effect: Up to 4–6 hours
• Administration: Oral tablet, taken with or without food (though high-fat meals may delay absorption)
• Manufacturer compliance: Produced under strict pharmaceutical quality standards

Benefits

• Facilitates improved erectile function by increasing blood flow to the corpus cavernosum
• Supports psychological confidence and reduces performance-related anxiety
• Enhances the quality of intimate relationships through reliable functional support
• Allows for spontaneity in sexual activity due to an extended window of efficacy
• Provides a well-tolerated treatment option with a established safety profile when used as directed

Common use

Aurogra is indicated for the treatment of erectile dysfunction, a condition characterized by the consistent inability to achieve or sustain an erection adequate for sexual intercourse. It is used on an as-needed basis and should be taken approximately 30–60 minutes prior to anticipated sexual activity. Sexual stimulation is required for the medication to produce its intended effect. Aurogra is not indicated for use in women, children, or adolescents.

Dosage and direction

The recommended starting dose of Aurogra is 50mg, taken orally approximately one hour before sexual activity. Based on efficacy and tolerability, the dose may be increased to 100mg or decreased to 25mg. Dosage should not exceed 100mg within a 24-hour period. The tablet should be swallowed whole with a glass of water. It may be taken with or without food, though consumption with a high-fat meal may delay the onset of action.

Precautions

Prior to using Aurogra, patients should disclose their full medical history, including cardiovascular status, liver or kidney impairment, anatomical penile deformities, history of priapism, bleeding disorders, or active peptic ulceration. Use with caution in patients with left ventricular outflow obstruction or those with a history of sudden cardiac events. Avoid consumption of grapefruit or grapefruit juice, as it may increase plasma concentrations of Sildenafil. Alcohol consumption should be limited, as it may increase the risk of adverse effects such as dizziness or orthostatic hypotension.

Contraindications

Aurogra is contraindicated in patients with a known hypersensitivity to Sildenafil Citrate or any excipients in the formulation. Concurrent use with organic nitrates or nitric oxide donors (e.g., amyl nitrite) in any form is strictly prohibited due to the risk of severe hypotension. It is also contraindicated in patients with severe hepatic impairment, severe hypotension, recent stroke or myocardial infarction, unstable angina, or hereditary degenerative retinal disorders.

Possible side effect

Common side effects may include headache, flushing, dyspepsia, nasal congestion, dizziness, and visual disturbances such as altered color perception. Less frequently, patients may experience myalgia, back pain, or nausea. Priapism (a prolonged and painful erection lasting more than 4 hours) is a rare but serious adverse event requiring immediate medical attention to avoid permanent tissue damage. Sudden hearing loss or non-arteritic anterior ischemic optic neuropathy (NAION) have been reported in association with PDE5 inhibitor use, though causality is not firmly established.

Drug interaction

Aurogra may interact with alpha-blockers, antihypertensive agents, potent CYP3A4 inhibitors (e.g., ketoconazole, ritonavir), and other medications that affect blood pressure. Concomitant use with nitrates is absolutely contraindicated. Caution is advised when used with other PDE5 inhibitors or recreational drugs containing nitrates. Inform your healthcare provider of all prescription, over-the-counter, and herbal products you are taking.

Missed dose

Aurogra is not intended for regular daily dosing; it is taken on an as-needed basis. Therefore, the concept of a “missed dose” does not apply. Do not take an extra dose to make up for a missed opportunity for sexual activity.

Overdose

In cases of suspected overdose, symptomatic management is advised. Expected effects may include severe hypotension, syncope, prolonged erection, and cardiovascular events. Priapism requires urgent urological intervention. Supportive measures should be initiated, including cardiovascular monitoring and appropriate hemodynamic support. There is no specific antidote for Sildenafil overdose.

Storage

Store Aurogra tablets at room temperature (15–30°C), in a dry place, protected from light and moisture. Keep out of reach of children and pets. Do not use beyond the expiration date printed on the packaging.

Disclaimer

This information is intended for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any new medication or making changes to your treatment plan. Do not disregard professional medical advice or delay seeking it based on information presented here.

Reviews

Clinical studies and post-marketing surveillance indicate that Aurogra is effective and generally well-tolerated in appropriately selected patients. Many users report improved erectile function and satisfaction with sexual performance. Individual responses may vary, and adherence to prescribing guidelines is critical for optimal outcomes. Consult your physician to determine if Aurogra is suitable for you.